TECHNETIUM TC-99M TILMANOCEPT - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for technetium tc-99m tilmanocept and what is the scope of freedom to operate?
Technetium tc-99m tilmanocept
is the generic ingredient in one branded drug marketed by Cardinal Health 414 and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.Technetium tc-99m tilmanocept has thirty patent family members in twelve countries.
One supplier is listed for this compound.
Summary for TECHNETIUM TC-99M TILMANOCEPT
| International Patents: | 30 |
| US Patents: | 2 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 7 |
| DailyMed Link: | TECHNETIUM TC-99M TILMANOCEPT at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for TECHNETIUM TC-99M TILMANOCEPT
Generic Entry Date for TECHNETIUM TC-99M TILMANOCEPT*:
Constraining patent/regulatory exclusivity:
Dosage:
INJECTABLE;INJECTION |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for TECHNETIUM TC-99M TILMANOCEPT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| John O. Prior | Early Phase 1 |
| Eben Rosenthal | Phase 2 |
| National Cancer Institute (NCI) | Phase 2 |
US Patents and Regulatory Information for TECHNETIUM TC-99M TILMANOCEPT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardinal Health 414 | LYMPHOSEEK KIT | technetium tc-99m tilmanocept | INJECTABLE;INJECTION | 202207-001 | Mar 13, 2013 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Cardinal Health 414 | LYMPHOSEEK KIT | technetium tc-99m tilmanocept | INJECTABLE;INJECTION | 202207-001 | Mar 13, 2013 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Cardinal Health 414 | LYMPHOSEEK KIT | technetium tc-99m tilmanocept | INJECTABLE;INJECTION | 202207-001 | Mar 13, 2013 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for TECHNETIUM TC-99M TILMANOCEPT
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 5743905 | ⤷ Try a Trial | |
| China | 102301429 | ⤷ Try a Trial | |
| Japan | 4056701 | ⤷ Try a Trial | |
| South Korea | 20110115148 | COMPOSITION FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID(DTPF)-DEXTRAN | ⤷ Try a Trial |
| Japan | 6833892 | ⤷ Try a Trial | |
| Japan | 2002544243 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for TECHNETIUM TC-99M TILMANOCEPT
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1178838 | 1590025-1 | Sweden | ⤷ Try a Trial | PRODUCT NAME: TILMANOCEPT; REG. NO/DATE: EU/1/14/955 20141120 |
| 1178838 | 300736 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119 |
| 1178838 | 122015000033 | Germany | ⤷ Try a Trial | PRODUCT NAME: TILMANOCEPT; REGISTRATION NO/DATE: C(2014) 8901 FINAL 20141119 |
| 1178838 | 15C0033 | France | ⤷ Try a Trial | PRODUCT NAME: TILMANOCEPT; REGISTRATION NO/DATE: EU/1/14/955 20141121 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
